Walking away from stroke: simple step goals may stabilize artery plaque
NCT ID NCT04053166
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a 6-month home-based walking program could reduce dangerous bleeding inside carotid artery plaque in people with significant blockages but no stroke symptoms. Fifty-six participants either followed an individualized step goal (with coaching) or received usual care. The researchers used MRI to measure plaque vulnerability before and after the program.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- individualized home-based physical activity (walking program with step goals and coaching)
- What this could lead to
- If it works, this could show that a simple walking program helps stabilize carotid plaque, potentially reducing stroke risk without surgery.
- What could go wrong
- This is a small, early study with only 56 participants, so results may not apply widely. The intervention is modest (increasing steps), and the main outcome is an MRI marker, not actual stroke reduction.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
56 people
The number who actually took part.
- Started
-
Dec 2019
- Finished
-
Sep 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient with an carotid atheromatous plaque with ≥ 50% North American Symptomatic Carotid Endarterectomy Trial (NASCET) stenosis * Patient from vascular surgery department of the Louis Pradel Hospital of the Hospices Civils de Lyon, but not operated * Males and females aged over 18 years old * No contra-indication to physical activity with index performance (PS) \< 2 * Available and voluntary to invest in the study throughout its duration (6 months) * Able to understand, read and write French; * a social security system or similar; * Having dated and signed informed consent. Exclusion Criteria: * Transient ischemic attack (TIA) or ipsilateral cerebral infarction less than 6 months * History of ipsilateral carotid surgery or cervical irradiation; * Cancer, heart failure, seropositivity; * Coronary risk; * Renal failure (Cockcroft clearance of creatinine \< 30 milliliter/minute (mL/min); * Contraindication and precautions for use related to Prohance: hypersensitivity to the active substance or to any of the constituents of Prohance, renal insufficiency with clearance \<30 ml / min / 1.73 m², probability of convulsions during the higher examination in patients with epilepsy or brain injury, pregnancy, breastfeeding; * Contraindication to MRI: ferromagnetic material (including pacemaker, implantable defibrillators, cardiac valve prostheses, cochlear implants, neurostimulators, implanted automated injection equipment, intraocular metallic foreign bodies, neurosurgical and vascular clips); * Carotid occlusion; * ipsilateral intracranial stenosis; * Risk of pregnancy or proven pregnancy on interrogation data. Breastfeeding; * Patient under guardianship, under curatorship or safeguard of justice; * inability to express consent; * uncontrolled cardiological or neurological diseases; * Impossibility of being followed for medical, social, geographical or psychological reasons throughout the duration of the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Carotid atherosclerosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Louis Pradel
Bron, 69500, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new CT scanner see carotid plaques better?
- Could a green tea compound prevent second heart attacks?
- Tiny molecules in artery plaques may reveal stroke clues
- Can a cholesterol drug shrink artery plaque in diabetes patients?
- Can Omega-3 boost statins to fight artery plaque in diabetes?
- Can common heart drugs prevent artery blockage in diabetes?